Andrea Apolo, Brian C Baumann, Hikmat Al-Ahmadie, Leslie Ballas, Rick Bangs, Kenneth Brothers, Stephanie Cooper Greenberg, Scott Delacroix, James J Dignam, Jason A Efstathiou, Adam S Feldman, Jared C Foster, Noah M Hahn, Emma Hall, Donna E Hansel, Jean Hoffman-Censits, Ashish M Kamat, Sophia C Kamran, Francesca Khani, Seth P Lerner, Robert Lipman, Bhupinder Mann, David McConkey, James McKiernan, Tracy L Rose, Angela B Smith, Catherine Tangen, Abdul Tawab Amiri, Chana Weinstock, Pamela J West, Matthew I Milowsky, Peter C Black
{"title":"NCI关于下一代非肌肉浸润性膀胱癌临床试验计划会议总结。","authors":"Andrea Apolo, Brian C Baumann, Hikmat Al-Ahmadie, Leslie Ballas, Rick Bangs, Kenneth Brothers, Stephanie Cooper Greenberg, Scott Delacroix, James J Dignam, Jason A Efstathiou, Adam S Feldman, Jared C Foster, Noah M Hahn, Emma Hall, Donna E Hansel, Jean Hoffman-Censits, Ashish M Kamat, Sophia C Kamran, Francesca Khani, Seth P Lerner, Robert Lipman, Bhupinder Mann, David McConkey, James McKiernan, Tracy L Rose, Angela B Smith, Catherine Tangen, Abdul Tawab Amiri, Chana Weinstock, Pamela J West, Matthew I Milowsky, Peter C Black","doi":"10.1177/23523735251319185","DOIUrl":null,"url":null,"abstract":"<p><p>The National Cancer Institute organized a virtual Clinical Trials Planning Meeting (CTPM) on 'Defining the next generation of clinical trials with combination therapies in non-muscle invasive bladder cancer (NMIBC)' led by the Bladder Cancer Task Force of the NCI Genitourinary Cancers Steering Committee. The purpose of this meeting was to accelerate advances in clinical trials for patients with high-risk NMIBC. The meeting delivered a multidisciplinary expert consensus on optimal strategies for next-generation clinical trial designs in NMIBC with prioritization of combination therapies. Two clinical trial concepts were developed for potential implementation within the National Clinical Trials Network.</p>","PeriodicalId":54217,"journal":{"name":"Bladder Cancer","volume":"11 1","pages":"23523735251319185"},"PeriodicalIF":2.2000,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11863732/pdf/","citationCount":"0","resultStr":"{\"title\":\"Summary from the NCI clinical trials planning meeting on next generation of clinical trials in non-muscle invasive bladder cancer<sup />.\",\"authors\":\"Andrea Apolo, Brian C Baumann, Hikmat Al-Ahmadie, Leslie Ballas, Rick Bangs, Kenneth Brothers, Stephanie Cooper Greenberg, Scott Delacroix, James J Dignam, Jason A Efstathiou, Adam S Feldman, Jared C Foster, Noah M Hahn, Emma Hall, Donna E Hansel, Jean Hoffman-Censits, Ashish M Kamat, Sophia C Kamran, Francesca Khani, Seth P Lerner, Robert Lipman, Bhupinder Mann, David McConkey, James McKiernan, Tracy L Rose, Angela B Smith, Catherine Tangen, Abdul Tawab Amiri, Chana Weinstock, Pamela J West, Matthew I Milowsky, Peter C Black\",\"doi\":\"10.1177/23523735251319185\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The National Cancer Institute organized a virtual Clinical Trials Planning Meeting (CTPM) on 'Defining the next generation of clinical trials with combination therapies in non-muscle invasive bladder cancer (NMIBC)' led by the Bladder Cancer Task Force of the NCI Genitourinary Cancers Steering Committee. The purpose of this meeting was to accelerate advances in clinical trials for patients with high-risk NMIBC. The meeting delivered a multidisciplinary expert consensus on optimal strategies for next-generation clinical trial designs in NMIBC with prioritization of combination therapies. Two clinical trial concepts were developed for potential implementation within the National Clinical Trials Network.</p>\",\"PeriodicalId\":54217,\"journal\":{\"name\":\"Bladder Cancer\",\"volume\":\"11 1\",\"pages\":\"23523735251319185\"},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2025-02-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11863732/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Bladder Cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/23523735251319185\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bladder Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/23523735251319185","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
Summary from the NCI clinical trials planning meeting on next generation of clinical trials in non-muscle invasive bladder cancer.
The National Cancer Institute organized a virtual Clinical Trials Planning Meeting (CTPM) on 'Defining the next generation of clinical trials with combination therapies in non-muscle invasive bladder cancer (NMIBC)' led by the Bladder Cancer Task Force of the NCI Genitourinary Cancers Steering Committee. The purpose of this meeting was to accelerate advances in clinical trials for patients with high-risk NMIBC. The meeting delivered a multidisciplinary expert consensus on optimal strategies for next-generation clinical trial designs in NMIBC with prioritization of combination therapies. Two clinical trial concepts were developed for potential implementation within the National Clinical Trials Network.
期刊介绍：
Bladder Cancer is an international multidisciplinary journal to facilitate progress in understanding the epidemiology/etiology, genetics, molecular correlates, pathogenesis, pharmacology, ethics, patient advocacy and survivorship, diagnosis and treatment of tumors of the bladder and upper urinary tract. The journal publishes research reports, reviews, short communications, and letters-to-the-editor. The journal is dedicated to providing an open forum for original research in basic science, translational research and clinical medicine that expedites our fundamental understanding and improves treatment of tumors of the bladder and upper urinary tract.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
